Back to News
Market Impact: 0.3
Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock Up
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
The FDA accepted Biohaven's resubmitted New Drug Application for Vyglxia (troriluzole) for review as a treatment for spinocerebellar ataxia, a rare neurodegenerative disorder. Acceptance for review is a regulatory milestone, not an approval; the article provides no review timeline or additional clinical or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BHVN0.55
More News
- AMD, Marvell among market cap stock movers on Thursday
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data